Alex Sigal

Low seroprevalence of neutralizing antibodies to gorilla adenovirus 32 (GRAd32) in southern African populations supports evaluation of this vector platform for HIV vaccine development

This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.

Multifaceted B-cell response to transient HIV viraemia in elite controllers

This study investigates the B-cell response to transient HIV viraemia in elite controllers, revealing TLM heterogeneity and the role of innate-like B cells.

Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.

Interference with HIV infection of the first cell is essential for viral clearance in a pre-exposure prophylaxis model

The paper develops a mathematical model to predict HIV infection clearance with PrEP, showing that reducing infection frequency per cell is more effective than reducing viral burst size.

Viral apoptosis evasion via the MAPK pathway by use of a host long noncoding RNA

This study shows HIV-1 evades apoptosis in macrophages by manipulating the MAP2K1/ERK2 pathway to dysregulate lincRNA-p21, and suggests MAP2K1/ERK2 inhibitors as a therapeutic strategy.

Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death

The paper shows that partial inhibition of HIV transmission can increase live infected lymph node cells by reducing cell death, even with fewer HIV DNA copies per cell.